The histone deacetylase inhibitor romidepsin synergizes with lenalidomide and enhances tumor cell death in T-cell lymphoma cell lines

We investigated the cytotoxic interactions of romidepsin, a histone deacetylase inhibitor, and lenalidomide, an immunomodulatory agent, in a T-cell lymphoma preclinical model. Hut-78 and Karpas-299 cells were treated with romidepsin and lenalidomide alone and in combination. The interaction between...

Descripción completa

Detalles Bibliográficos
Autores principales: Cosenza, Maria, Civallero, Monica, Fiorcari, Stefania, Pozzi, Samantha, Marcheselli, Luigi, Bari, Alessia, Ferri, Paola, Sacchi, Stefano
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5079402/
https://www.ncbi.nlm.nih.gov/pubmed/27657380
http://dx.doi.org/10.1080/15384047.2016.1219820

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5079402/
https://www.ncbi.nlm.nih.gov/pubmed/27657380
http://dx.doi.org/10.1080/15384047.2016.1219820

Ejemplares similares